Puxitatug Samrotecan

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against B7-H4 (V-set domain-containing T-cell activation inhibitor 1; VTCN1; B7x; B7S1) linked to samrotecan, which is coposed of a linker and the topoisomerase-1 inhibitor (TOP1i; TOP-Ii) exatecan, with potential antineoplastic activity. Upon administration, the anti-B7-H4 monoclonal antibody moiety of puxitatug samrotecan targets and binds to B7-H4 expressed on tumor cells. Upon binding and internalization, exatecan is released, binds to TOP1 and stabilizes cleaved DNA-TOP1 complexes. This prevents DNA re-ligation, induces irreversible DNA strand breaks, prevents DNA repair, and leads to cycle arrest and apoptosis specifically in tumor cells expressing B7-H4. B7-H4, a member of the B7 family of immune modulators, is upregulated in a variety of tumor cell types and tumor-associated macrophages. It negatively regulates T-cell immune responses.

**Synonyms:** - ADC AZD8205 - AZD 8205 - AZD-8205 - AZD8205 - Anti-B7-H4/TOP1i ADC AZD8205 - Anti-B7-H4/Topoisomerase I Inhibitor ADC AZD8205 - Antibody-drug Conjugate AZD8205 - B7-H4 TOP1i ADC AZD8205 - PUXITATUG SAMROTECAN